ALLO - CIK 0001737287
The table below shows Allogene Therapeutics, Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $51.69M | $75.22M | $83.16M | $61.90M | $173.31M | $183.35M |
| Short-term investments | - | - | - | - | $283.99M | $644.56M |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $257.75M |
| $303.39M |
| $459.12M |
| $528.82M |
| $471.32M |
| $845.13M |
| Property, plant & equipment | $72.84M | $86.06M | $99.48M | $112.84M | $122.99M | $118.84M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $415.90M | $548.71M | $642.84M | $817.08M | $1.04B | $1.23B |
| Accounts payable | $4.27M | $5.39M | $5.90M | $13.89M | $10.26M | $10.39M |
| Total current liabilities | $32.51M | $35.52M | $37.08M | $54.52M | $48.17M | $94.32M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $123.36M | $126.53M | $130.60M | $151.21M | $122.23M | $148.21M |
| Retained earnings | -$2.01B | -$1.82B | -$1.56B | -$1.23B | -$903.35M | -$646.34M |
| Total equity | $292.54M | $422.18M | $512.23M | $666.88M | $916.41M | $1.08B |